68Ga-PSMA-11与18F-Fluciclovine PET/CT在前列腺癌复发10例病例系列中的比较
本研究对10例前列腺癌复发患者进行了68Ga-PSMA-11与18F-Fluciclovine PET/CT的头对头比较。结果发现5例(50%)患者18F-Fluciclovine阴性而68Ga-PSMA-11阳性,2例(20%)两者均阳性但68Ga-PSMA-11显示额外淋巴结转移,3例(30%)两者均阴性。作者认为该病例系列提示68Ga-PSMA-11 PET/CT检测率优于18F-Fluciclovine PET/CT,并建议开展前瞻性直接比较试验。
要点
- 10例前列腺癌复发患者中,5例(50%)18F-Fluciclovine阴性而68Ga-PSMA-11阳性。
- 2例(20%)两者均阳性,但68Ga-PSMA-11显示额外淋巴结转移。
- 3例(30%)两者均阴性;作者认为68Ga-PSMA-11检测率更优。
核心结论
- 该病例系列提示,在复发性前列腺癌患者中,68Ga-PSMA-11 PET/CT的检测率较18F-Fluciclovine PET/CT有所提高。
- 作者建议应启动旨在直接比较这两种显像剂的前瞻性试验。
研究设计与样本
- 本研究为头对头比较,纳入10例前列腺癌复发患者,比较68Ga-PSMA-11与18F-Fluciclovine PET/CT。
- 288例前列腺癌复发患者被纳入一项68Ga-PSMA-11 PET/CT定位复发灶的前瞻性研究(ClinicalTrials.gov标识NCT02940262)。
- 研究者回顾性识别出其中10例在入组前接受了临床指征的18F-Fluciclovine PET/CT的患者。
主要发现
- 两次扫描的中位间隔时间为2.2个月(范围0.2-4.2个月)。
- 18F-Fluciclovine PET/CT扫描时中位前列腺特异性抗原(PSA)值为1.0 ng/mL(均值4.7 ng/mL;范围0.13-18.1 ng/mL)。
- 68Ga-PSMA-11 PET/CT扫描时中位PSA值为1.1 ng/mL(均值6.2 ng/mL;范围0.24-31.3 ng/mL)。
- 10例患者中5例(50%)18F-Fluciclovine阴性而68Ga-PSMA-11阳性。
- 10例患者中2例(20%)两者均阳性,但68Ga-PSMA-11 PET/CT显示额外淋巴结转移;3例(30%)两者均阴性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本文为病例系列。
- 作者建议应启动旨在直接比较两种显像剂的前瞻性试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This was a head-to-head comparison between 68Ga-labeled prostate-specific membrane antigen (PSMA)-11 and 18F-fluciclovine PET/CT in a series of 10 patients with prostate cancer (PCa) recurrence. Methods: In total, 288 patients with PCa recurrence were enrolled in a prospective study of 68Ga-PSMA-11 PET/CT imaging for recurrent disease localization (ClinicalTrials.gov identifier NCT02940262). We retrospectively identified 10 patients who underwent clinically indicated 18F-fluciclovine PET/CT prior to enrollment. Results: The median time between the 2 scans was 2.2 mo (range, 0.2-4.2 mo). The median prostate-specific antigen (PSA) value was 1.0 ng/mL (mean, 4.7 ng/mL; range, 0.13-18.1 ng/mL) and 1.1 ng/mL (mean, 6.2 ng/mL; range, 0.24-31.3 ng/mL) at the time of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT, respectively. Five of 10 patients (50%) were negative with 18F-fluciclovine but positive with 68Ga-PSMA-11 PET/CT. Two of 10 patients (20%) were positive with both 18F-fluciclovine and 68Ga-PSMA-11 PET/CT, but 68Ga-PSMA-11 PET/CT showed additional lymph nodes metastasis. Three of 10 patients (30%) were negative with both 18F-fluciclovine and 68Ga-PSMA-11 PET/CT. Conclusion: This case series suggests improved detection rates for 68Ga-PSMA-11 PET/CT when compared with 18F-fluciclovine PET/CT in patients with recurrent PCa. Prospective trials designed to directly compare the two should be initiated.
引用
- Calais J, Fendler WP, Herrmann K, et al. Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. J Nucl Med. 2017. PMID: 29242404. doi:10.2967/jnumed.117.203257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。